Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Liposomal MTP-PE: a promising new biologic response modifier

J B Gano1, E S Kleinerman

  • 1Department of Cell Biology, University of Texas M.D. Anderson Cancer Center, Houston, USA.

Oncology Nursing Forum
|June 1, 1995
PubMed
Summary

Liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) shows promise in extending progression-free intervals for osteosarcoma patients. Further research is needed to determine its full efficacy and long-term effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines.

Oncogenesis·2013
Same author

MS-275 sensitizes osteosarcoma cells to Fas ligand-induced cell death by increasing the localization of Fas in membrane lipid rafts.

Cell death & disease·2012
Same author

Intratumor murine interleukin-12 gene therapy suppressed the growth of local and distant Ewing's sarcoma.

Cancer gene therapy·2006
Same author

Biologic response modifiers in pediatric cancer.

Hematology/oncology clinics of North America·2001
Same author

Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEI-p53 complexes.

Cancer gene therapy·2001
Same author

Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase IIalpha gene transfer is independent of topoisomerase IIbeta.

British journal of cancer·2001

Area of Science:

  • Immunology
  • Pharmacology
  • Oncology

Background:

  • Liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) is a novel biologic response modifier.
  • MTP-PE activates macrophages, enhancing their tumoricidal capabilities.

Purpose of the Study:

  • To provide a comprehensive overview of MTP-PE.
  • To detail its mechanism of action, administration, and clinical applications.

Main Methods:

  • Literature review of published articles, abstracts, and conference proceedings.
  • Synthesis of data on MTP-PE's effects and patient outcomes.

Main Results:

  • MTP-PE has demonstrated an extended progression-free interval in relapsed osteosarcoma patients.

Related Experiment Videos

  • Ongoing studies are evaluating MTP-PE in combination with chemotherapy to assess recurrence rates.
  • MTP-PE can be safely administered in outpatient settings, with manageable side effects.

    • Conclusions:

    • Nurses require thorough knowledge of MTP-PE for effective patient care, including administration and side effect management.
    • Increased use of MTP-PE necessitates enhanced nursing understanding of its effects and psychosocial implications.